Chronic cough is one of the most common, and longest-lasting symptoms of Long COVID. An experimental drug called ADX-629 is currently being investigated in clinical trials to help reduce inflammation and inhibit the biochemical activity that serves as the cough’s root cause. 

We at Responsum are collaborating with Aldeyra Therapeutics to help spread awareness about clinical trials, along with information about how to get involved. For this purpose, we’ve launched an initiative for the Long COVID community that includes pre-screening patients with chronic cough and connecting them to trial doctors for potential participation in this important study. This particular study is in phase 2 and looking to recruit 50 participants. Keep reading to find out what’s involved, and if you might be eligible. 

What is ADX-629?

Developed by Aldeyra Therapeutics, ADX-629 is a novel, first-in-class, orally administered investigational drug being investigated for its activity across different types of immunological diseases. The goal of the current trial is to test the safety and tolerability of ADX-629, as well as its effect on patients’ cough.

ADX-629 is currently being used for research purposes only and will only be given to participants that qualify for the clinical trial. ADX-629 not approved by the U.S. Food and Drug Administration (FDA) or commercially available. 

The ADX-629 Chronic Cough Study

The randomized, placebo-controlled, cross-over study will test ADX-629 in approximately 50 people across the U.S.

Key points about the study:

• Potential participants will be informed about the trial before they begin any trial-related procedures
• Participants will undergo various medical assessments, including blood draws, physical exams, and monitoring of their cough via questionnaires and a 24-hour cough recorder
• All qualified participants will be given both ADX-629 and placebo, however, since the study is “double-blinded” both researchers and participants will not know which one the participant will receive first 
• Each qualified participant will be in the trial for about 3 months and will attend 10 clinic visits 
• Participants will be asked to follow all instructions given to them and attend scheduled study visits at their pre-arranged study site.
• Participants will be reminded that participating in a clinical trial is voluntary and they can decide to stop participating at any time 

As part of the study, participants will receive study medication and study-related medical care at no cost to them. Participants will be reimbursed per study visit completed.

Eligibility

To be considered eligible for participation in ADX-629, you must meet requirements including but not limited to:

• 18 to 80 years of age
• Have had a cough for 1 year or more
• Be a non-smoker 
• Able and willing to attend 10 study visits 

If participants pass the online pre-screening form, they will be contacted by a Responsum representative and matched with a trial doctor nearest them.

Participation in a clinical trial

There are many benefits and risks to consider before participating in a clinical trial. Joining a clinical trial is an important decision. It is recommended that patients talk with their doctor and loved ones before participating in a clinical trial.

Click here to learn more about the chronic cough clinical research study.